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Side effectsLevetiracetam is a relatively new antiepileptic drug that has previously not been associated with severe derma-
tological side effects. We report the case of a 31-year-old male treated with levetiracetam for seizures who sub-
sequently developed a mycosis fungoides-like drug reaction that resolved upon dosage reduction.
© 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Levetiracetam (LEV) is a new antiepileptic drug that is effective
in adults and children with partial-onset seizures or idiopathic or
symptomatic generalized seizures. Levetiracetam is a derivative of
S-enantiomer pyrrolidone and is chemically similar to piracetam,
preventing excitatory or inhibitory neurotransmitters from binding to
the receptor. The effects of LEV onhigh-voltage neuron-speciﬁc Ca2+ in-
ﬂux through Ca2+ channels, gated GABA, and glycine are suggested to
inhibit or reverse currents. Na+ or T-type Ca2+ does not have an effect
on the channels. Levetiracetam-related side effects were observed at a
rate of 17.2–51.3% and usually occurred within the ﬁrst 5 months of
treatment [1]. Central nervous system side effects are themost common
side effects but are usuallymild; other common side effects are irritabil-
ity, drowsiness, and dizziness [2].
Antiepileptic drug-induced skin reactions, most commonly with
phenytoin (PHT), carbamazepine (CBZ), oxcarbazepine (OXC), pheno-
barbital (PB), lamotrigine (LTG), and zonisamide (ZNS) and sometimes
with pyrimidione, valproic acid (VPA), topiramate (TPM), gabapentin
(GBP), tiagabine (TGB), and LEV are rarely reported [3].
Mycosis fungoides (MF) is a cutaneous T-cell lymphoma character-
ized by the malignant proliferation of T cells with phenotypic and func-
tional properties of T-helper cells [4]. The etiology of this uncommon
lymphoma is unknown. Genetic, infective, and environmental causes
have all been implicated. Most patients have a severe course of thecal School Neurology, 16059/
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en access article under the CC BY-NCdisease. Therefore, treatment should provide optimal beneﬁts while
minimizing toxicity as much as possible. Mycosis fungoides is a low-
grade lymphoproliferative disorder caused by CD4+ lymphocytes [5].
Mycosis fungoides-like skin reactions resulting from PHT, CBZ, and
OXC have been previously reported in the literature.
We report the case of a patient who was taking the anticonvulsant
drug levetiracetam and in whom skin lesions developed that showed
histological features suggestive of mycosis fungoides.
2. Case
A thirty-one-year-old male patient presented at Uludag University
Medical Faculty Department of Neurology Epilepsy Clinic with general-
ized seizures. Once asleep, the patient, who had no history of systemic
diseases, was given JTKN twice in a 10-month period. After neurological
examination, routine blood tests, and MRI (Fig. 1) of the patient, all of
which were normal, LEV (500 mg/day) was started. During the wake-
fulness and sleep portions of the patient's EEG, left frontal theta- and
sharp-wave activities were observed (Fig. 2). Approximately 2 months
after LEV initiation, a pale, pinkish, macular erythemawith unclear bor-
ders was observed at the sides of the abdomen (Fig. 3).
On physical examination, there was no cervical lymphadenopathy
or hepatomegaly. Laboratory test results revealed no peripheral blood
eosinophilia, normal renal and liver enzymes, and negative vasculitic
parameters (ANA, anti-nDNA). A skin punch biopsy revealed mild inﬁl-
tration of perivascular mononuclear inﬂammatory cells in the dermis.
Immunohistochemical staining was positive for CD3–CD4–CD7 and
CD8 lymphocytes (Figs. 4a–d). Mycosis fungoides, as a reaction to-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Cranial MRI was unremarkable.
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by reducing his dosage of LEV and of other medications capable of caus-
ing rare skin reactions; the patient was subsequently started on VPA
500 mg/day p.o.
We concluded that a mycosis fungoides-like drug reaction was the
cause. The patient recovered by reducing his dosage of LEV and of
other medications capable of causing rare skin reactions; VPA andFig. 2. Spike–wave and theta activities were observetopical corticosteroid treatments were started. The patient was seizure-
free and recovered from the skin lesions.
3. Discussion
Although antiepileptic drug-induced skin reactions, including
maculopapular rash, are very rare, cases such as Stevens–Johnsond over the left frontotemporal area in the EEG.
Fig. 3. Abdomen with pale, pinkish, macular, erythematous borders.
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fungoides is a peripheral non-Hodgkin's T-cell neoplastic process,
representing the most common type of primary cutaneous malignant
lymphoma. Anticonvulsant-induced pseudolymphomas usually
develop within 2 to 8 weeks of drug use. Although skin lesions usually
resolve within 3 to 4 weeks after discontinuing the offending agents,
long-term follow-up is needed to assure the absence of lymphopro-
liferative malignancy [6]. Our patient developed a pale, pinkish,
erythematous, macular lesion on both sides of the abdomen approx-
imately 3 months after LEV initiation.
There are two main groups of drug-induced pseudolymphomas:
those that clinically and histological simulate cutaneous lymphomas
and those known as hypersensitivity syndromes. Pseudolymphomas
cannot be differentiated from true lymphomas through clinical,
pathological, or molecular ﬁndings. A deﬁnitive test for diagnosis is
the resolution of the lesions after themedication involved is suspended
[7].Fig. 4. a–d. Immunohistochemical staining was posMycosis fungoides-like skin reactions to PHT, PB, CBZ, and OXC have
been previously reported in the literature. Rosenthal et al. reported
patients showing histological features suggestive of MF who were taking
the anticonvulsant drug diphenylhydantoin [8]. After using LEV, our
patient, upon histopathological examination, exhibitedmild perivascular
mononuclear inﬂammatory cells in the papillary dermis suggestive of an
anticonvulsant-induced pseudolymphoma. Clinical and histopathological
differential diagnosis included skin manifestation of connective tissue
diseases. However, a detailed history along with dermatological exami-
nations failed to reveal a connective tissue disease.
The choice of treatment for patients with MF varies depending on
the stage involved and the site of the lesions. Treatment should be consid-
ered in all patients, irrespective of staging, as it has been shown to im-
prove the prognosis even in the early stage of disease [9]. PUVA, topical
nitrogen mustard, and topical corticosteroids are the main options for
early-stage disease. The patient was diagnosed with a drug-induced
pseudolymphoma, and topical corticosteroid therapy was initiated.itive for CD3–CD4–CD7 and CD8 lymphocytes.
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lymphoma, and PHT, CBZ, and OXC can induce MF-like skin reactions.
Mycosis fungoides-associated pseudolymphoma was ﬁrst mentioned
in the literature in 1982 as a result of the use of diphenylhydantoin
[8] and has been referred to by different names, such as, in 1985, phe-
nytoin-related MF-like lesions and, in 1997, also caused by phenyt-
oin, pseudomycosis fungoides syndrome. In recent years (1990 and
2001), in cases of CBZ use, MF-associated pseudolymphoma has
been referred to as mimicking mycosis fungoides; in 2003, it was
termed pseudomycosis fungoides [10–14].
In 2011, Navarro and his colleagues reported a 45-year-old female
patient who used OXC for 2 months and developed a mycosis
fungoides-like syndrome, as evidenced by a skin biopsy [15].
4. Conclusions
In our case, cutaneous lesions were evaluated by a dermatologist
after approximately 3 months of taking LEV. After making the differen-
tial diagnosis of MF disease, it was decided that it was compatible with
MF histopathologically. It has been observed in the literature that
drugs such as CBZ, OXC, PHT, and PB have an MF-like impact mecha-
nism. However, our case involved LEV, which is a different drug than
those referenced in the literature.
There have been no prior reported cases of MF-like disease associat-
ed with LEV. We think that this could be the ﬁrst appearance in the lit-
erature of MF-like disease associated with LEV and a different
mechanism of action that causes an MF-like skin reaction.
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